Note: composite drawn from patterns across multiple clinical reviews, not a description of any single company or founder.
“Basically CBT” is one of the more common phrases I hear early in a clinical review, and it is almost never accurate. Not because founders are being dishonest — most of them believe it when they say it — but because “basically” is doing an enormous amount of work in that sentence.
What “Basically CBT” Usually Means
In one review, I sat down with a product team that described their core feature as “basically CBT” — thought-pattern prompts, mood tracking, a few reframing exercises pulled loosely from cognitive behavioral therapy. On the surface, the language was right. Underneath it, none of the actual structure was there: no fidelity to the protocol, no sequencing that mirrors how CBT is delivered clinically, no measurement of whether the reframing exercises were producing the outcome CBT is designed to produce.
That gap is common, and it isn’t usually the result of cutting corners. It’s what happens when a strong product team, without a clinical lead in the room, builds something that resembles a therapeutic modality closely enough to name it — without the clinical scaffolding that makes the modality actually work.
Why It Matters More Than It Looks Like It Should
A mislabeled modality isn’t just a marketing inaccuracy. It’s a liability that sits quietly until a diligence team, a journalist, or a state regulator asks the product to show its work — and “basically CBT” is not an answer that survives that question. By the time it surfaces, it’s usually attached to a term sheet, a press cycle, or a user base that was told something the product couldn’t actually back up.
By the time it surfaces, it’s usually attached to a term sheet, a press cycle, or a user base that was told something the product couldn’t back up.
What the Fix Actually Looks Like
The fix isn’t rebranding the feature or softening the claim. It’s walking through the product with the clinical and product teams together, mapping what the intervention is actually doing against what a validated modality requires, and closing the gap in the underlying structure — not just the copy. Done early, that’s a few months of focused work. Done after a diligence team or a reporter finds it first, it’s a much more public problem.
This is the gap a fractional CCO closes before it becomes a headline — not after.
CASE NOTES
Two Similar Mental Health Startups. One Had Clinical Oversight From Day One.
Case Notes • 4 min read
Note: composite drawn from patterns across multiple clinical reviews, not a description of any single company or founder.
Two mental health startups, similar stage, similar model, similar total addressable market. On paper, in a pitch deck, they would have scored almost identically. Eighteen months later, only one of them was still operating.
The One Without Clinical Oversight
The first company scaled fast, added states quickly, and treated clinical licensing as a background compliance task rather than a product decision. It hit a cross-state licensing gap mid-scale — the kind of issue that looks small in a monthly ops review and turns into a raise-stalling problem the moment a diligence team starts asking which states the clinical staff are actually licensed in. The raise stalled for months while the gap got fixed retroactively, in the middle of a fundraising process, under the worst possible time pressure.
The One With Clinical Oversight
The second company built clinical oversight into the operating model from the start — a clinical advisor with real authority, not a name on an advisory slide, involved early enough to flag licensing requirements before they became blockers. When that company went through diligence, the exact question that stalled the first company’s raise was already answered, documented, and ready to hand over.
Clinical oversight isn’t a cost center. It’s a diligence shortcut — and it’s cheaper early than it is mid-raise.
The Lesson That Generalizes
Clinical oversight gets treated, too often, as a cost center — something to add once the company can afford it. The companies that get through diligence cleanly are the ones that treat it as a diligence shortcut instead: the earlier it’s built in, the fewer expensive surprises show up at the exact moment a company can least afford them.
Clinical oversight isn’t a cost center. It’s a diligence shortcut — happy to walk through what that looks like for a specific portfolio company.